237 related articles for article (PubMed ID: 24004830)
21. Rational design, synthesis and in vitro evaluation of allylidene hydrazinecarboximidamide derivatives as BACE-1 inhibitors.
Jain P; Wadhwa PK; Rohilla S; Jadhav HR
Bioorg Med Chem Lett; 2016 Jan; 26(1):33-7. PubMed ID: 26614409
[TBL] [Abstract][Full Text] [Related]
22. A novel beta-site amyloid precursor protein cleaving enzyme (BACE) isoform regulated by nonsense-mediated mRNA decay and proteasome-dependent degradation.
Tanahashi H; Tabira T
Neurosci Lett; 2007 Nov; 428(2-3):103-8. PubMed ID: 17961921
[TBL] [Abstract][Full Text] [Related]
23. Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design.
Park H; Lee S
J Am Chem Soc; 2003 Dec; 125(52):16416-22. PubMed ID: 14692784
[TBL] [Abstract][Full Text] [Related]
24. Amyloid precursor protein and BACE function as oligomers.
Multhaup G
Neurodegener Dis; 2006; 3(4-5):270-4. PubMed ID: 17047367
[TBL] [Abstract][Full Text] [Related]
25. Computational methods in the discovery and design of BACE-1 inhibitors.
Kacker P; Bottegoni G; Cavalli A
Curr Med Chem; 2012; 19(36):6095-111. PubMed ID: 23072352
[TBL] [Abstract][Full Text] [Related]
26. Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads.
Huang Y; Strobel ED; Ho CY; Reynolds CH; Conway KA; Piesvaux JA; Brenneman DE; Yohrling GJ; Moore Arnold H; Rosenthal D; Alexander RS; Tounge BA; Mercken M; Vandermeeren M; Parker MH; Reitz AB; Baxter EW
Bioorg Med Chem Lett; 2010 May; 20(10):3158-60. PubMed ID: 20399652
[TBL] [Abstract][Full Text] [Related]
27. Unveiling a novel transient druggable pocket in BACE-1 through molecular simulations: Conformational analysis and binding mode of multisite inhibitors.
Di Pietro O; Juárez-Jiménez J; Muñoz-Torrero D; Laughton CA; Luque FJ
PLoS One; 2017; 12(5):e0177683. PubMed ID: 28505196
[TBL] [Abstract][Full Text] [Related]
28. Fragment-guided approach to incorporating structural information into a CoMFA study: BACE-1 as an example.
Salum LB; Valadares NF
J Comput Aided Mol Des; 2010 Oct; 24(10):803-17. PubMed ID: 20661764
[TBL] [Abstract][Full Text] [Related]
29. Design and development of BACE-1 inhibitors.
Cumming JN; Iserloh U; Kennedy ME
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):536-56. PubMed ID: 15338962
[TBL] [Abstract][Full Text] [Related]
30. Tyramine fragment binding to BACE-1.
Kuglstatter A; Stahl M; Peters JU; Huber W; Stihle M; Schlatter D; Benz J; Ruf A; Roth D; Enderle T; Hennig M
Bioorg Med Chem Lett; 2008 Feb; 18(4):1304-7. PubMed ID: 18226904
[TBL] [Abstract][Full Text] [Related]
31. Conformational transition in the substrate binding domain of β-secretase exploited by NMA and its implication in inhibitor recognition: BACE1-myricetin a case study.
Chakraborty S; Kumar S; Basu S
Neurochem Int; 2011 Jul; 58(8):914-23. PubMed ID: 21354237
[TBL] [Abstract][Full Text] [Related]
32. Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates.
Bowers S; Xu YZ; Yuan S; Probst GD; Hom RK; Chan W; Konradi AW; Sham HL; Zhu YL; Beroza P; Pan H; Brecht E; Yao N; Lougheed J; Tam D; Ren Z; Ruslim L; Bova MP; Artis DR
Bioorg Med Chem Lett; 2013 Apr; 23(7):2181-6. PubMed ID: 23465612
[TBL] [Abstract][Full Text] [Related]
33. Pharmacophore based 3D-QSAR modeling, virtual screening and docking for identification of potential inhibitors of β-secretase.
Palakurti R; Vadrevu R
Comput Biol Chem; 2017 Jun; 68():107-117. PubMed ID: 28288354
[TBL] [Abstract][Full Text] [Related]
34. Haloperidol inhibits Memapsin 2: innovation by docking simulation and in vitro assay.
Al-Nadaf AH; Taha MO; Aldal'in HK
Pak J Pharm Sci; 2015 Jan; 28(1):139-46. PubMed ID: 25553677
[TBL] [Abstract][Full Text] [Related]
35. Alzheimer's disease: identification and development of β-secretase (BACE-1) binding fragments and inhibitors by dynamic ligation screening (DLS).
Fernández-Bachiller MI; Horatscheck A; Lisurek M; Rademann J
ChemMedChem; 2013 Jul; 8(7):1041-56. PubMed ID: 23757181
[TBL] [Abstract][Full Text] [Related]
36. Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor.
Iserloh U; Pan J; Stamford AW; Kennedy ME; Zhang Q; Zhang L; Parker EM; McHugh NA; Favreau L; Strickland C; Voigt J
Bioorg Med Chem Lett; 2008 Jan; 18(1):418-22. PubMed ID: 17980584
[TBL] [Abstract][Full Text] [Related]
37. Development and characterization of a novel membrane assay for full-length BACE-1 at pH 6.0.
Saric A; Brügge Lz; Müller-Pompalla D; Rysiok T; Ousson S; Permanne B; Quattropani A; Busch M; Beher D; Hussain I
J Biomol Screen; 2013 Mar; 18(3):277-85. PubMed ID: 23023105
[TBL] [Abstract][Full Text] [Related]
38. Self-organizing molecular field analysis on human β-secretase nonpeptide inhibitors: 5, 5-disubstituted aminohydantoins.
Li Z; Zhou M; Wu F; Li R; Ding Z
Eur J Med Chem; 2011 Jan; 46(1):58-64. PubMed ID: 21093114
[TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of potent and selective BACE-1 inhibitors.
Björklund C; Oscarson S; Benkestock K; Borkakoti N; Jansson K; Lindberg J; Vrang L; Hallberg A; Rosenquist A; Samuelsson B
J Med Chem; 2010 Feb; 53(4):1458-64. PubMed ID: 20128595
[TBL] [Abstract][Full Text] [Related]
40. Interaction mechanism exploration of HEA derivatives as BACE1 inhibitors by in silico analysis.
Wu Q; Li X; Gao Q; Wang J; Li Y; Yang L
Mol Biosyst; 2016 Apr; 12(4):1151-65. PubMed ID: 26915506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
